Dianthus Therapeutics, Inc. (DNTH) vs Travere Therapeutics, Inc. (TVTX)

Dianthus Therapeutics, Inc. and Travere Therapeutics, Inc. are both Biotechnology companies. Travere Therapeutics, Inc. is the larger, with a market value of $5.7B against $5.1B — 1.1× the size. Travere Therapeutics, Inc. grew revenue faster over the last twelve months: 77.1% against −60.8%. Travere Therapeutics, Inc. has the higher net margin (−7.35% vs −10,097.0%) and the higher return on invested capital (−18.3% vs −47.7%). Across the 17 metrics below, Travere Therapeutics, Inc. leads on 11 and Dianthus Therapeutics, Inc. on 6.

Valuation

Metric DNTH TVTX Biotechnology median
P/E n/m n/m 7.88
P/S 2,605.77 9.40 11.47
P/B 4.23 226.59 2.52
Price to free cash flow n/m 383.94 21.16
EV/EBITDA n/m 281.89 0.74
EV/Sales 2,140.00 9.59 10.73
Earnings yield (4.69%) (0.76%) (28.84%)
Free cash flow yield (3.14%) 0.26% (23.03%)

Profitability

Metric DNTH TVTX Biotechnology median
Gross margin 100.00% 98.60% 65.16%
Operating margin (11,441.39%) (6.84%) 0.00%
Net margin (10,096.95%) (7.35%) 0.00%
Free cash flow margin (8,177.99%) 2.56% 0.00%
Return on equity (26.07%) (151.79%) (57.72%)
Return on assets (24.98%) (6.42%) (49.22%)
Return on invested capital (47.74%) (18.31%) 0.00%

Growth

Metric DNTH TVTX Biotechnology median
Revenue growth (TTM) (60.77%) 77.12% 5.64%
EPS growth (last fiscal year) (64.71%) 92.89% —
Revenue growth, 5-year CAGR — 19.87% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNTH TVTX Biotechnology median
Debt to equity 0.00 24.58 0.00
Current ratio 26.10 4.05 4.73
Net debt to EBITDA 2.20 2.27 0.96

Dividend

Metric DNTH TVTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DNTH TVTX Biotechnology median
Market cap 5.07b 5.66b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack